Article Data

  • Views 495
  • Dowloads 136

Original Research

Open Access

Distribution of HPV genotypes and the relationship with CIN

  • Hong Ma1
  • Yumei Li1,*,
  • Zhiqiang Chen1
  • Liping Liu1
  • Hui Xu1
  • Xiaoyue Yang2

1Dermatology and Venereology Department,Zhenjiang City (China)

2Gynaecology and Obstetrics Department, Jiangsu University Hospital, Zhenjiang City (China)

DOI: 10.12892/ejgo3888.2017 Vol.38,Issue 4,August 2017 pp.601-606

Published: 10 August 2017

*Corresponding Author(s): Yumei Li E-mail: yumeili@ujs.edu.cn

Abstract

Objective: To study the distribution of human papillomavirus (HPV) genotypes in population of hospital opportunistic screening and the relationship with cervical intraepithelial neoplasia (CIN) among women. Materials and Methods: A retrospective analysis was performed in 14,991 women who were undergoing HPV genotype testing and 253 inpatients who were undergoing conization pathological with CIN and with pre-HPV test at Jiangsu University Hospital between July 2013 and July 2015. Results: Of these, 25.99% were infected by HPV and 20.37% for high-risk HPV (hr-HPV), the highest prevalence of hr-HPV and multiple hr-HPV were all in the 55- to 64-year-old group (χ2 = 37.125, p < 0.01, χ2 = 43.668, p < 0.01). The most prevalent genotype is HPV52, then descending order were HPV16 and 58. On the basis of 253 inpatients, CIN I were 78, CIN II were 67, CIN III were 108. Before conization, hr-HPV positive in CIN I lesions were 74.36% (58/78) and CIN II were 94.03% (63/67), while in CIN III lesions there were 94.44% (102/108) (χ2 =17.936, p < 0.01). The most frequent HPV genotype was HPV 16, followed by HPV 58 and 52. Infection with multiple- hr-HPV seemed to have no relationship with the severity of pathology increased (χ2 =1.888, p > 0.01). Conclusion: This study established the prevalence of HPV genotypes that is similar to the population of CIN, except HPV 16 and HPV 52, 58 were also found in a large proportion of women, HPV 18 was not the most important. Therefore, in the future, a HPV vaccine covering HPV 52/16/58 should be used in this region compared to the currently available vaccine for the prevention strategy in the population.

Keywords

Human papillomavirus (HPV); Genotype; Cervical intraepithelial neoplasia (CIN).

Cite and Share

Hong Ma,Yumei Li,Zhiqiang Chen,Liping Liu,Hui Xu,Xiaoyue Yang. Distribution of HPV genotypes and the relationship with CIN. European Journal of Gynaecological Oncology. 2017. 38(4);601-606.

References

[1] Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., et al.: “Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012”. Int. J. Cancer, 2015, 136, E359.

[2] Li S., Hu T., Lv W., Zhou H., Li X., Yang R., et al.: “Changes in prevalence and clinical characteristics of cervical cancer in the People’s Republic of China: a study of 10,012 cases from a nationwide working group”. Oncologist, 2013, 18, 1101.

[3] Giorgi R.P., Franceschi S., Ronco G.: “HPV prevalence and accuracy of HPV testing to detect high grade cervical intraepithelial neoplasia”. Int. J. Cancer, 2012, 130, 1387.

[4] Nam K., Chung S., Kim J., Jeon S., Bae D.: “Factors associated with HPV persistence after conization in patients with negative margins”. J. Gynecol. Oncol., 2009, 20, 91.

[5] McCredie M.R., Sharples K.J., Paul C., Baranyai J., Medley G., Jones R.W., et al.: “Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study”. Lancet Oncol., 2008, 9, 425.

[6] Ho G.Y., Burk R.D., Klein S., Kadish A.S., Chang C.J., Palan P., et al.: “Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia”. J. Natl. Cancer Inst., 1995, 87, 1365.

[7] Wang R., Guo X.L., Wisman G.B., Schuuring E., Wang W.F., Zeng Z.Y.: “Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China”. BMC Infect Dis., 2015, 15, 257.

[8] Argyri E., Papaspyridakos S., Tsimplaki E., Michala L., Myriokefalitaki E., Papassideri I., et al.: “A cross sectional study of HPV type prevalence according to age and cytology”. BMC Infect. Dis., 2013, 13, 53.

[9] Yuce K., Pinar A., Salman M.C., Alp A., Sayal B., Dogan S., Hascelik G.: “Detection and genotyping of cervical HPV with simultaneous cervical cytology in Turkish women: a hospital-based study”. Arch. Gynecol. Obstet., 2012, 286, 203.

[10] Agarossi A., Ferrazzi E., Parazzini F., Perno C.F., Ghisoni L.: “Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy”. J. Med. Virol., 2009, 81, 529.

[11] Anderson L., O'Rorke M., Jamison J., Wilson R., Gavin A., HPV Working Group members: “Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: new data from northern Ireland and a systematic review and meta-analysis”. J. Med. Virol., 2013, 85, 295.

[12] de Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N., Bosch F.X.: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis”. Lancet Infect. Dis., 2007, 7, 453.

[13] Vaccarella S., Franceschi S., Herrero R., Muñoz N., Snijders P.J., Clifford G.M., et al.: “IARC HPV Prevalence Surveys Study Group. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys”. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 326.

[14] Pista A.; de Oliveira C.F., Cunha M.J., Paixao M.T., Real O.: “Prevalence of human papillomavirus infection in women in Portugal: The CLEOPATRE Portugal Study”. Int. J. Gynecol. Cancer, 2011, 21, 1150.

[15] Balbi G., Napolitano A., Giordano F., Capuano S., Manganaro M.A., Di Martino L., et al.: “Role of the association of high-risk HPV identified by real-time PCR in cervical preneoplastic lesions”. Eur. J. Gynaecol. Oncol., 2012, 33, 467.

[16] Trottier H., Mahmud S., Costa M.C., Sobrinho J.P., Duarte Franco E., Rohan T.E., et al.: “Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 1274.

[17] Cuschieri K.S., Cubie H.A., Whitley M.W., Gilkison G., Arends M.J., Graham C., McGoogan E.: “Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study”. J. Clin. Pathol., 2005, 58, 946.

[18] Ye J., Cheng X., Chen X., Ye F., Lü W., Xie X.: “Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study”. Virol. J., 2010, 7, 66.

[19] De Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al.: “Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional survey”. Lancet Oncol., 2010, 11, 1048.

[20] Choi Y.J., Park J.S.: “Clinical significance of human papillomavirus genotyping”. J. Gynecol. Oncol., 2016, 27, e21.

[21] Schiller J.T., Castellsagué X., Villa L.L., Hildesheim A.: “An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results”. Vaccine, 2008, 26, K53.

[22] Markowitz L.E., Dunne E.F., Saraiya M., Chesson H.W., Curtis C.R., Gee J., et al.: “Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)”. MMWR Recomm. Rep., 2014, 63, 1.

[23] Joura E.A, Giuliano A.R., Iversen O.E., Bouchard C., Mao C., Mehlsen J., et al.: “A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women”. N. Engl. J. Med., 2015, 372, 711.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top